Acpharis

Acpharis is a private, pre-revenue biotech company providing a computational platform for early-stage drug discovery, with a focus on oncology. Its core technology includes computational solvent mapping for binding site identification and a high-performance protein-protein docking software, validated by its performance in the CAPRI challenge and widespread academic use. The company employs a hybrid business model, offering both its software tools and tailored scientific services to partners, positioning itself as an enabler for identifying novel drug targets and molecules. Led by its scientific founders and CEO, Acpharis aims to reduce the time and cost associated with the initial phases of drug development.

Computational drug discovery platform featuring computational solvent mapping for druggable binding site identification and classification, and a high-performance protein-protein docking software consistently ranked among the best in the CAPRI challenge.

Acpharis competes in the computational drug discovery software and services market, which includes large players like Schrödinger and Dassault Systèmes (BIOVIA), as well as numerous specialized startups and academic consortia. Its differentiation lies in the specific accuracy of its protein-protein docking software and its focus on solvent mapping for binding site characterization.